Katerina Rok Song, Ram Hari Chapagain, Dipesh Tamrakar, Rajeev Shrestha, Piush Kanodia, Shipra Chaudhary, T Anh Wartel, Jae Seung Yang, Deok Ryun Kim, Jinae Lee, Eun Lyeong Park, Haeun Cho, Jiyoung Lee, Patchara Thaisrivichai, Sridhar Vemula, Bo Mi Kim, Birendra Gupta, Tarun Saluja, Ruchir Kumar Pansuriya, Ravi Ganapathy, Yeong Ok Baik, Young Jin Lee, Suhi Jeon, Youngran Park, Howard L Her, Youngshin Park, Julia A Lynch
BACKGROUND: In October, 2017, WHO launched a strategy to eliminate cholera by 2030. A primary challenge in meeting this goal is the limited global supply capacity of oral cholera vaccine and the worsening of cholera outbreaks since 2021. To help address the current shortage of oral cholera vaccine, a WHO prequalified oral cholera vaccine, Euvichol-Plus was reformulated by reducing the number of components and inactivation methods. We aimed to evaluate the immunogenicity and safety of Euvichol-S (EuBiologics, Seoul, South Korea) compared with an active control vaccine, Shanchol (Sanofi Healthcare India, Telangana, India) in participants of various ages in Nepal...
May 2024: Lancet Global Health